Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/99880
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy
Author: Yeung, D.
Tang, C.
Vidovic, L.
White, D.
Branford, S.
Hughes, T.
Yong, A.
Citation: Blood, 2015; 126(25):2720-2723
Publisher: American Society of Hematology
Issue Date: 2015
ISSN: 0006-4971
1528-0020
Statement of
Responsibility: 
David T. Yeung, Carine Tang, Ljiljana Vidovic, Deborah L. White, Susan Branford, Timothy P. Hughes, Agnes S. Yong
Abstract: Killer immunoglobulin-like receptors (KIRs) on natural killer (NK) cells have been shown to predict for response in chronic phase-chronic myeloid leukemia (CP-CML) patients treated with tyrosine kinase inhibitors. We performed KIR genotyping in 148 newly diagnosed CP-CML patients treated with a novel sequential imatinib/nilotinib strategy aimed at achievement of optimal molecular responses at defined time points. We found the presence of KIR2DL5B to be associated with inferior transformation-free survival and event-free survival and an independent predictor of inferior major molecular response (BCR-ABL1 ≤0.1%) and molecular response 4.5 (BCR-ABL1 ≤0.0032%). This suggests a critical early role for NK cells in facilitating response to imatinib that cannot be overcome by subsequent intensification of therapy. KIR genotyping may add valuable prognostic information to future baseline predictive scoring systems in CP-CML patients and facilitate optimal frontline treatment selection.
Keywords: Genotype
Rights: © 2015 by The American Society of Hematology
DOI: 10.1182/blood-2015-07-655589
Grant ID: http://purl.org/au-research/grants/nhmrc/1059165
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.